The REDEEM study, led by Dr. Joshua Wong and colleagues from the Baker Heart and Diabetes Institute in Melbourne, Australia, was published in the American Heart Journal. It focuses on adults aged 40 years and older who had completed potentially cardiotoxic cancer therapy at least five years earlier and who also had at least one established heart-failure risk factor. Participants underwent comprehensive echocardiographic screening to detect subtle cardiac changes before symptoms emerged.
The key findings of the study are as follows:
- Out of 1,124 cancer survivors assessed, 604 underwent complete echocardiographic evaluation.
- Subclinical or stage B heart failure (SBHF) was detected in 145 participants, representing about 24 percent of those screened.
- The average three-dimensional left ventricular ejection fraction remained preserved at around 53 percent.
- Global longitudinal strain averaged 15.6 percent, indicating early, subclinical cardiac dysfunction.
- Reduced cardiorespiratory fitness (VO₂peak ≤18 ml/kg/min) was observed in 39 percent of participants tested.
- Abnormal global longitudinal strain was associated with higher body mass index, diabetes, older age, and prior anthracycline exposure.
- Lower exercise capacity was linked only to increasing age.
- Abnormal strain and diminished fitness did not consistently overlap, suggesting distinct underlying mechanisms.
Eligible participants with SBHF are now being randomly assigned either to a multidisciplinary cardio-oncology disease-management program or to usual care. The intervention includes guideline-based neurohormonal therapy, supervised exercise training, and aggressive risk-factor control. Investigators will measure changes in peak oxygen uptake over six months as the primary outcome to see whether early treatment can prevent progression to overt heart failure.
Dr. Wong and the research team emphasize that there are currently no clear clinical guidelines for heart-failure surveillance in cancer survivors. Their baseline findings demonstrate that a structured, risk-based screening pathway is both practical and revealing, identifying a substantial subset of seemingly healthy individuals who already harbor silent cardiac injury years after chemotherapy.
These results set the stage for the interventional phase of REDEEM, which the authors describe as the first randomized controlled trial designed to test whether proactive, risk-guided disease management can delay or prevent symptomatic heart failure in this vulnerable group.
Reference:
Wong, J., Smith, J., Soh, C. H., Howden, E., Talbot, J. S., Nolan, M., Whitmore, K., Wright, L., Sherriff, A., Sivaraj, E., Wheeler, G., Wiltshire, K., Campbell, P., Ramkumar, S., Tam, C., & Marwick, T. H. (2025). Risk-Guided Disease Management To Prevent Heart Failure In Adult Cancer Survivors of Previous Cardiotoxic Cancer Treatments: Baseline Results of the REDEEM Trial. American Heart Journal. https://doi.org/10.1016/j.ahj.2025.09.009
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.